Kiora Pharmaceuticals, Inc. (KPRX)

NCM – Цена в реальном времени. Валюта: USD

2.44

+0.03 (1.24%)

При закрытии: May 12, 2026, 4:00 PM EDT

08.05.2026

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline of small molecules for the treatment of retinal diseases. First Quarter 2026 and Recent Highlights Enrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodate the strong patient demand to participate in the trial Publication of ABACUS-1 clinical trial results in Nature Medicine, providing external validation of KIO-301's potential for vision restoration in patients with late-stage retinitis pigmentosa Continued progress in the Phase 2 KLARITY study of KIO-104, with an upcoming, pre-defined safety review to support advancement to the next dose level Kiora has an operational runway into late 2028, well beyond the anticipated clinical data readouts from both ongoing clinical trials Subsequent to the end of the quarter, Kiora executed a strategic equity financing, led by Perceptive Advisors that further strengthens the balance sheet "We are encouraged by the continued progress across both of our clinical programs, including the strong momentum we are seeing with KIO-301 enrollment," said Brian Strem, Ph.D.

14.04.2026

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine. The publication adds clinical detail to a program aimed at restoring light responsiveness with a small molecule "photoswitch" in patients with the advanced inherited retinal disease, retinitis pigmentosa.

02.04.2026

Kiora Pharmaceuticals Announces Management Team Changes

Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that Eric J. Daniels, M.D.

25.03.2026

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a year-end business update on its pipeline of small molecules for the treatment of retinal diseases. Key fourth-quarter, full-year 2025, and recent corporate highlights include: Advanced KIO-301 from regulatory clearance to patient dosing in ABACUS-2, a Phase 2 randomized, controlled clinical trial in patients with advanced retinitis pigmentosa.

19.02.2026

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET. A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the IR homepage and under the News & Events section.

27.01.2026

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease, to its Scientific Advisory Board. As an advisor, Dr. Sakamoto, currently the Chair of Ophthalmology at Kagoshima University, will contribute clinical and scientific insights to Kiora as it develops new therapeutics to address retinal diseases with high unmet needs.

01.12.2025

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on additional and novel formulations of the KIO-100 family of compounds, This patent allows for additional delivery options, expanding the potential therapeutic utility of the active pharmaceutical ingredient (API) in KIO-104. This newly issued patent specifically covers a novel formulation of the API in KIO-104.

Видео

No Data

There is no data to display

Пресс-релизы

08.05.2026

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

14.04.2026

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

02.04.2026

Kiora Pharmaceuticals Announces Management Team Changes

Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that Eric J. Daniels, M.D.

25.03.2026

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Kiora Pharmaceuticals, Inc. (KPRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Kiora Pharmaceuticals, Inc. (KPRX)

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Kiora Pharmaceuticals Announces Management Team Changes

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Видео

No Data

Пресс-релизы

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Kiora Pharmaceuticals Announces Management Team Changes

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Kiora Pharmaceuticals Announces Management Team Changes

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Видео

No Data

Пресс-релизы

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Kiora Pharmaceuticals Announces Management Team Changes

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Search stocks

Kiora Pharmaceuticals, Inc. (KPRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Kiora Pharmaceuticals, Inc. (KPRX)

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Kiora Pharmaceuticals Announces Management Team Changes

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Видео

No Data

Пресс-релизы

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Kiora Pharmaceuticals Announces Management Team Changes

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Kiora Pharmaceuticals Announces Management Team Changes

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Видео

No Data

Пресс-релизы

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Kiora Pharmaceuticals Announces Management Team Changes

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials